We can’t show the full text here under this license. Use the link below to read it at the source.
Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials
Early-Onset Obesity and Response to Tirzepatide Treatment: Analysis of SURMOUNT Clinical Trials
AI simplified
Abstract
Participants with had a mean obesity duration of 20 years compared to 11 years for those with later-onset obesity.
- Individuals with early-onset obesity presented higher baseline BMI (40 kg/m) and waist circumference (118 cm) compared to those with later-onset obesity (37 kg/m and 112 cm, respectively).
- Lower baseline levels of HbA1c (5.48% vs. 5.60%) and triglycerides (120 mg/dL vs. 130 mg/dL) were observed in participants with early-onset obesity.
- Systolic blood pressure was lower in participants with early-onset obesity at baseline (121 mmHg) compared to later-onset individuals (125 mmHg).
- Weight loss and improvements in waist circumference, HbA1c, triglycerides, and systolic blood pressure with tirzepatide at 72 weeks were consistent across both early- and later-onset obesity subgroups.
AI simplified
Key numbers
20 ± 12 years
Mean Obesity Duration
Compared to 11 ± 8 years in later-onset obesity group.
-23%
Body Weight Reduction
vs. -22% in later-onset obesity at 72 weeks.
40 ± 7 kg/m
BMI at Baseline
Compared to 37 ± 6 kg/m in later-onset obesity group.